CN112543645A - 用于治疗疾病的贝伐珠单抗的缓冲制剂 - Google Patents

用于治疗疾病的贝伐珠单抗的缓冲制剂 Download PDF

Info

Publication number
CN112543645A
CN112543645A CN201980040536.7A CN201980040536A CN112543645A CN 112543645 A CN112543645 A CN 112543645A CN 201980040536 A CN201980040536 A CN 201980040536A CN 112543645 A CN112543645 A CN 112543645A
Authority
CN
China
Prior art keywords
formulation
antibody
use according
certain aspects
retinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980040536.7A
Other languages
English (en)
Chinese (zh)
Inventor
C·尤南
W·登达姆龙维特
M·希利-弗里德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prospective Therapy Co
Original Assignee
Prospective Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prospective Therapy Co filed Critical Prospective Therapy Co
Publication of CN112543645A publication Critical patent/CN112543645A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201980040536.7A 2018-04-17 2019-04-17 用于治疗疾病的贝伐珠单抗的缓冲制剂 Pending CN112543645A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862658772P 2018-04-17 2018-04-17
US62/658772 2018-04-17
US201862776686P 2018-12-07 2018-12-07
US62/776686 2018-12-07
PCT/US2019/027790 WO2019204380A1 (en) 2018-04-17 2019-04-17 Buffered formulations of bevacizumab for use of treating diseases

Publications (1)

Publication Number Publication Date
CN112543645A true CN112543645A (zh) 2021-03-23

Family

ID=66429576

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980040536.7A Pending CN112543645A (zh) 2018-04-17 2019-04-17 用于治疗疾病的贝伐珠单抗的缓冲制剂

Country Status (12)

Country Link
US (1) US20210230261A1 (enExample)
EP (1) EP3781199A1 (enExample)
JP (1) JP2021522180A (enExample)
KR (1) KR20210011923A (enExample)
CN (1) CN112543645A (enExample)
AU (1) AU2019256289A1 (enExample)
BR (1) BR112020021255A2 (enExample)
CA (1) CA3097123A1 (enExample)
IL (1) IL278041A (enExample)
MX (1) MX2020010968A (enExample)
SG (1) SG11202010178XA (enExample)
WO (1) WO2019204380A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113546172A (zh) * 2020-04-24 2021-10-26 山东大学齐鲁医院 Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP7713950B2 (ja) * 2020-03-04 2025-07-28 上海復宏漢霖生物技術股▲フン▼有限公司 ベバシズマブを含む薬物製剤
US20210403568A1 (en) * 2020-06-29 2021-12-30 Cai Gu Huang Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080268051A1 (en) * 2007-04-30 2008-10-30 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
WO2017117202A1 (en) * 2015-12-29 2017-07-06 Oncobiologics, Inc. Buffered formulations of bevacizumab
CN106924184A (zh) * 2017-03-29 2017-07-07 烟台大学 一种眼部玻璃体注射用多囊脂质体及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
WO2012019136A2 (en) * 2010-08-05 2012-02-09 Forsight Vision 4, Inc. Injector apparatus and method for drug delivery
WO2015200905A2 (en) * 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080268051A1 (en) * 2007-04-30 2008-10-30 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
WO2017117202A1 (en) * 2015-12-29 2017-07-06 Oncobiologics, Inc. Buffered formulations of bevacizumab
CN106924184A (zh) * 2017-03-29 2017-07-07 烟台大学 一种眼部玻璃体注射用多囊脂质体及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113546172A (zh) * 2020-04-24 2021-10-26 山东大学齐鲁医院 Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用

Also Published As

Publication number Publication date
AU2019256289A1 (en) 2020-11-12
BR112020021255A2 (pt) 2021-02-02
KR20210011923A (ko) 2021-02-02
MX2020010968A (es) 2021-01-08
SG11202010178XA (en) 2020-11-27
US20210230261A1 (en) 2021-07-29
IL278041A (en) 2020-11-30
CA3097123A1 (en) 2019-10-24
WO2019204380A1 (en) 2019-10-24
EP3781199A1 (en) 2021-02-24
JP2021522180A (ja) 2021-08-30

Similar Documents

Publication Publication Date Title
US12371481B2 (en) Methods for treating age-related macular degeneration
KR20210011923A (ko) 질환 치료 용도를 위한 베바시주맙의 완충 제제
CN112739323B (zh) 含有高浓度vegf受体融合蛋白的制剂
EP3397281B1 (en) Buffered formulations of bevacizumab
JP2024170515A (ja) 抗体－薬物コンジュゲートの製剤及びその凍結乾燥方法
KR102590359B1 (ko) 항체 제형
JP7089121B2 (ja) 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤
JP7794730B2 (ja) 抗ｐｄ－１／ｈｅｒ２二重特異性抗体を含む製剤及びその調製方法と使用
US20130017197A1 (en) Stabilized antibody preparations and uses thereof
WO2023202685A1 (en) Pharmaceutical compositons containing anti-her2 antibody for subcutaneous administration
CA2966758C (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
EA042435B1 (ru) Стабильный препарат раствора белка, содержащего анти-vegf антитело в высокой концентрации

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210323

WD01 Invention patent application deemed withdrawn after publication